BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month Low at $4.15

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s share price hit a new 52-week low on Thursday . The company traded as low as $4.15 and last traded at $4.15, with a volume of 11160 shares. The stock had previously closed at $4.21.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $13.83.

BioCryst Pharmaceuticals Stock Down 1.2 %

The stock has a market cap of $857.58 million, a price-to-earnings ratio of -3.46 and a beta of 1.90. The firm's 50 day moving average is $5.13 and its two-hundred day moving average is $5.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $89.19 million. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Bank of New York Mellon Corp boosted its holdings in shares of BioCryst Pharmaceuticals by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 767,571 shares of the biotechnology company's stock valued at $5,434,000 after acquiring an additional 8,087 shares in the last quarter. Arete Wealth Advisors LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 64.7% in the third quarter. Arete Wealth Advisors LLC now owns 23,300 shares of the biotechnology company's stock valued at $165,000 after acquiring an additional 9,150 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 2,388 shares in the last quarter. Fifth Third Bancorp boosted its holdings in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company's stock worth $25,000 after buying an additional 3,500 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 6.1% during the third quarter. Panagora Asset Management Inc. now owns 727,480 shares of the biotechnology company's stock worth $5,151,000 after buying an additional 41,971 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.